Hami expects Maxibufen sales growth

Published: 2007-05-14 06:58:00

Updated: 2007-05-14 06:58:00

Hanmi Pharm said its independently developed Maxibufen (dexibuprofen) syrup, an analgesic and antipyretic agent for children, will become the second growth engine for the company following the launch of Amordipine. The sales of Maxibufen are estimated at 10 billion won level this year.

Hanmi t...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK